Vlasic & Roth LLC is an experienced operating partner of middle-market healthcare and technology companies. Our team of experts engages alongside financial partners to operationalize growth strategies, optimize operational efficiency, and prioritize sustainable performance improvement efforts. V&R brings a rigorous approach to these M&A activities before, during, and post-integration. Their work establishes a durable infrastructure for future M&A activity and improved valuations.
Once engaged, our team performs a systematic assessment of integration gaps and then executes a prioritized list of changes in partnership with employees throughout each company. V&R’s founders believe that engagement from leadership through the frontline is critical for value creation and sustainability, which is why V&R’s approach focuses on aligning a firm’s People, Process, and Technology (in that order) with the evolving needs of each market. V&R wins alongside their clients by co-investing with world-class investment firms.
Jeff is a leader in healthcare transformation and operations. Prior to co-founding V&R, he worked as an Emergency Medicine Physician at Michigan Medicine and Hurley Medical Center. Jeff leads the Healthcare Performance Improvement Team at V&R, which currently serves hospitals, health systems, vendors, payers, non-profits, and middle-market businesses.
Mike is an entrepreneur and advisor with 25 years of experience in business operations, technology implementations, and management of high-performance teams. His experience has regularly included board and P&L accountability. Mike is credentialed as a Certified Mergers & Acquisitions Advisor (CM&AA®), an Executive Coach, and a Technology Infrastructure Expert. Mike initially worked in IT management for Anheuser Busch and the Detroit Medical Center before spending the majority of his career as a leader of multiple information technology consultancies. Mike leads the Private Capital Advisory at V&R, which engages with organizations with revenues ranging in revenue from $10M-2B, as well as private capital investors and family offices.